First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa
Publication
, Conference
Dyke, C; Steinhubl, S; Rusconi, C; Aberle, L; Myles, S; Melloni, C; Harrington, R; Becker, R; Alexander, J; Kleiman, N
Published in: CIRCULATION
November 28, 2006
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
November 28, 2006
Volume
114
Issue
22
Start / End Page
2427 / 2427
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
79th Annual Scientific Session of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Dyke, C., Steinhubl, S., Rusconi, C., Aberle, L., Myles, S., Melloni, C., … Kleiman, N. (2006). First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa. In CIRCULATION (Vol. 114, pp. 2427–2427). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
Dyke, Christopher, Steven Steinhubl, Christopher Rusconi, Laura Aberle, Shelley Myles, Chiara Melloni, Robert Harrington, Robert Becker, John Alexander, and Neal Kleiman. “First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa.” In CIRCULATION, 114:2427–2427. LIPPINCOTT WILLIAMS & WILKINS, 2006.
Dyke C, Steinhubl S, Rusconi C, Aberle L, Myles S, Melloni C, et al. First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 2427–2427.
Dyke, Christopher, et al. “First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa.” CIRCULATION, vol. 114, no. 22, LIPPINCOTT WILLIAMS & WILKINS, 2006, pp. 2427–2427.
Dyke C, Steinhubl S, Rusconi C, Aberle L, Myles S, Melloni C, Harrington R, Becker R, Alexander J, Kleiman N. First-in-man experience of an antidote-controlled anticoagulant using RNA aptamer technology: Results of the phase IA evaluation of the REG1 anticoagulation system, a product for the controlled regulation of factor IXa. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 2427–2427.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
November 28, 2006
Volume
114
Issue
22
Start / End Page
2427 / 2427
Location
Chicago, IL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Conference Name
79th Annual Scientific Session of the American-Heart-Association
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology